PTO Reconsidering Validity Of One Of Pfizer’s Lipitor Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Patent & Trademark Office will re-examine whether claims covering the crystalline form of atorvastatin were disclosed in the prior art. The patent runs until January 2017 and is the latest expiring of five Lipitor patents listed in the “Orange Book.”
You may also be interested in...
Pfizer Lipitor Patents Valid, Infringed By Ranbaxy, Court Says
If affirmed on appeal, the ruling means that ANDA first filer Ranbaxy would be unable to launch atorvastatin generics before 2011.
Pfizer Lipitor Patents Valid, Infringed By Ranbaxy, Court Says
If affirmed on appeal, the ruling means that ANDA first filer Ranbaxy would be unable to launch atorvastatin generics before 2011.
One Of Two Pfizer Lipitor Patents Upheld By U.K. Court
The company says the British court’s ruling, which could keep Ranbaxy’s generic off the market until 2011, “has no bearing” on atorvastatin patent litigation in the U.S.